ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) has earned a consensus rating of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $62.43.
Several equities analysts have recently issued reports on CCXI shares. StockNews.com raised shares of ChemoCentryx from a "sell" rating to a "hold" rating in a research note on Wednesday, August 10th. HC Wainwright cut shares of ChemoCentryx from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $101.00 to $52.00 in a research report on Friday, August 5th. Canaccord Genuity Group initiated coverage on shares of ChemoCentryx in a research report on Thursday, August 4th. They set a "buy" rating and a $81.00 price objective for the company. Stifel Nicolaus cut shares of ChemoCentryx from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. Finally, Canaccord Genuity Group cut shares of ChemoCentryx from a "buy" rating to a "hold" rating and set a $52.00 price objective for the company. in a research report on Friday, August 5th.
Get
ChemoCentryx alerts:
ChemoCentryx Price Performance
CCXI stock opened at $51.37 on Wednesday. The company has a fifty day moving average price of $39.43 and a 200-day moving average price of $28.74. The company has a market capitalization of $3.67 billion, a P/E ratio of -27.18 and a beta of 1.25. ChemoCentryx has a 52-week low of $14.95 and a 52-week high of $51.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.54.
Insider Activity
In other news, CEO Thomas J. Schall sold 130,000 shares of ChemoCentryx stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,393,352 shares in the company, valued at $120,242,004.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Susan M. Kanaya sold 46,298 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.17, for a total transaction of $2,322,770.66. Following the transaction, the chief financial officer now directly owns 91,317 shares of the company's stock, valued at $4,581,373.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas J. Schall sold 130,000 shares of the firm's stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the transaction, the chief executive officer now directly owns 2,393,352 shares in the company, valued at $120,242,004.48. The disclosure for this sale can be found here. Insiders sold 213,760 shares of company stock worth $10,749,838 over the last three months. 8.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Engineers Gate Manager LP raised its position in ChemoCentryx by 4.4% in the first quarter. Engineers Gate Manager LP now owns 12,780 shares of the biopharmaceutical company's stock worth $320,000 after acquiring an additional 540 shares during the period. Teacher Retirement System of Texas raised its position in ChemoCentryx by 9.2% in the first quarter. Teacher Retirement System of Texas now owns 9,999 shares of the biopharmaceutical company's stock worth $251,000 after acquiring an additional 841 shares during the period. UBS Asset Management Americas Inc. raised its position in ChemoCentryx by 1.4% in the second quarter. UBS Asset Management Americas Inc. now owns 69,953 shares of the biopharmaceutical company's stock worth $1,733,000 after acquiring an additional 971 shares during the period. Victory Capital Management Inc. raised its position in ChemoCentryx by 7.5% in the second quarter. Victory Capital Management Inc. now owns 14,077 shares of the biopharmaceutical company's stock worth $349,000 after acquiring an additional 981 shares during the period. Finally, Level Four Advisory Services LLC raised its position in ChemoCentryx by 10.9% in the first quarter. Level Four Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company's stock worth $326,000 after acquiring an additional 1,276 shares during the period. 81.09% of the stock is owned by institutional investors.
ChemoCentryx Company Profile
(Get Rating)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
See Also
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
